undefined

Press Releases

Industry Events

Catalogue

Videos

03 Jul,2025

Kardium raises $250M to support pulsed field ablation system

Kardium announced today that it raised $250 million in a new financing round to support the launch of its pulsed field ablation system.

30 May,2025

Interpretation | Insights into the Prospects and Development of the Medical Device Industry from Medtronic's Financial Reports

Medtronic's FY2025 Financial Highlights and Industry Implications Medtronic's FY2025 financial reports show robust performance, with annual revenue reaching $33.63 billion (4.9% organic growth) and Q4 revenue at $8.9 billion (5.4% organic growth). Profitability improved significantly, with non-GAAP operating margins up 90 basis points. Key business segments thrived: Cardiovascular grew 6.3% organically, driven by pulsed field ablation (PFA) and TAVR technologies; Neuroscience advanced 5.2% via brain-computer interfaces like BrainSense™ aDBS; and Diabetes achieved six consecutive quarters of double-digit growth (11.5%) led by the MiniMed™ 780G system. The company plans to spin off its diabetes unit to focus on core areas, invested $2.7 billion (8% of revenue) in R&D, and secured over 130 global regulatory approvals in the past year. For Chinese medical device firms, key takeaways include: prioritizing R&D in core sectors (e.g., high-end devices, smart healthcare), enhancing brand visibility through academic collaborations, optimizing portfolios via strategic adjustments, and strengthening global compliance. Medtronic’s success underscores how technological innovation and adaptive strategies can drive market leadership, offering a blueprint for navigating industry transformation.

22 May,2025

OptaBlate BVN: Stryker's Nerve Ablation System Approved for Market by FDA

24 Apr,2025

In - Depth Analysis of Key Points of Catheter Technology in Vascular Interventional Procedures

01 Apr,2025

Ask an electrophysiologist: What roles do PFA and RFA play in the treatment of AFib?

Both are types of cardiac ablation, but are distinct in a few key ways. An expert weighs in on when and how they can be harnessed. It’s been called “the 21st century cardiovascular disease epidemic,” affecting millions every year and raising the odds of serious health risks. Atrial fibrillation (AFib), the most common type of heart rhythm disorder,1 is a major cause of stroke, heart failure, heart attack, dementia and death.2 About 1 in 3 to 5 people over the age of 45 will develop the condition,3 and it’s only becoming more prevalent: Between 2010 and 2019, cases rose from 33.5 million to 59 million globally—and these figures likely underestimate the impact, as many people don’t know they have AFib until they experience symptoms or a stroke. 4 What’s more, the number of people affected by AFib could increase by more than 60% by 2050, highlighting the critical need for effective treatment options.5

< 123 >